Next Article in Journal / Special Issue
Selection of Single-Domain Antibodies towards Western Equine Encephalitis Virus
Previous Article in Journal
Enhancers Improve the AID-Induced Hypermutation in Episomal Vector for Antibody Affinity Maturation in Mammalian Cell Display
Previous Article in Special Issue
Isolation and Characterization of Nanobodies against a Zinc-Transporting P-Type ATPase
Article Menu

Export Article

Open AccessArticle
Antibodies 2018, 7(4), 43; https://doi.org/10.3390/antib7040043

Properties of Fluorescent Far-Red Anti-TNF Nanobodies

1
Center of Molecular Biology and Biomedicine, Institute of Biology and Biomedicine, Lobachevsky State University, Nizhniy Novgorod 603950, Russia
2
Laboratory of Transplantation Immunology, National Research Center for Hematology, Moscow 125167, Russia
3
Institute of Biomedical Technologies, Nizhny Novgorod State Medical Academy, Nizhniy Novgorod 603005, Russia
4
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow 119991, Russia
5
Lomonosov Moscow State University, Moscow 119991, Russia
6
Institute of Gene Biology, Russian Academy of Sciences, Moscow 119334, Russia
*
Authors to whom correspondence should be addressed.
Received: 23 November 2018 / Revised: 12 December 2018 / Accepted: 13 December 2018 / Published: 15 December 2018
(This article belongs to the Special Issue Nanobody)
Full-Text   |   PDF [2314 KB, uploaded 17 December 2018]   |  

Abstract

Upregulation of the expression of tumor necrosis factor (TNF-α, TNF) has a significant role in the development of autoimmune diseases. The fluorescent antibodies binding TNF may be used for personalized therapy of TNF-dependent diseases as a tool to predict the response to anti-TNF treatment. We generated recombinant fluorescent proteins consisting of the anti-TNF module based on the variable heavy chain (VHH) of camelid antibodies fused with the far-red fluorescent protein Katushka (Kat). Two types of anti-TNF VHH were developed: one (BTN-Kat) that was bound both human or mouse TNF, but did not neutralize their activity, and a second (ITN-Kat) that was binding and neutralizing human TNF. BTN-Kat does not interfere with TNF biological functions and can be used for whole-body imaging. ITN-Kat can be evaluated in humanized mice or in cells isolated from humanized mice. It is able to block human TNF (hTNF) activities both in vitro and in vivo and may be considered as a prototype of a theranostic agent for autoimmune diseases. View Full-Text
Keywords: TNF; fluorescent; nanobodies; sensor; anti-cytokine therapy; autoimmune disease TNF; fluorescent; nanobodies; sensor; anti-cytokine therapy; autoimmune disease
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Gorshkova, E.N.; Efimov, G.A.; Ermakova, K.D.; Vasilenko, E.A.; Yuzhakova, D.V.; Shirmanova, M.V.; Mokhonov, V.V.; Tillib, S.V.; Nedospasov, S.A.; Astrakhantseva, I.V. Properties of Fluorescent Far-Red Anti-TNF Nanobodies. Antibodies 2018, 7, 43.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top